Pro-Pharmaceuticals Doses Cancer Patient With Davanat/5-FU

Pro-Pharmaceuticals has announced the dosing of a colorectal cancer patient in a Phase II trial of its Davanat/5-FU product candidate.

The Phase II clinical trial is in metastatic colorectal cancer patients who have disease progression after receiving standard chemotherapeutic regimens. The company initiated a Phase II, multicenter, open-label trial to evaluate the efficacy and safety of intravenous Davanat in combination with 5-Fluorouracil (5-FU) when administered in monthly cycles as third- or fourth-line therapy for metastatic colorectal cancer.

Seven medical centers will take part in this trial, which expects to enroll up to 38 patients and uses Simon's two-stage design.